Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure

European Journal of Clinical Investigation

Volumn 33, Issue 11, 2003, Pages 941-948

  Chin, B S P ^a   Blann, A D ^a   Gibbs, C R ^a   Chung, N A Y ^a   Conway, D G ^a   Lip, G Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Heart failure; Interleukin 6; Prognosis; Tissue factor; Vascular endothelial growth factor

Indexed keywords

FIBRINOGEN; INTERLEUKIN 6; PADGEM PROTEIN; THROMBOPLASTIN; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD RHEOLOGY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; ENDOTHELIUM INJURY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; MATHEMATICAL COMPUTING; MORBIDITY; MORTALITY; PLASMA VISCOSITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STROKE; THROMBOCYTE ACTIVATION; THROMBOSIS;

AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOOD VISCOSITY; DISEASE-FREE SURVIVAL; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PROGNOSIS; THROMBOPLASTIN; VON WILLEBRAND FACTOR;

EID: 0242469290     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2003.01252.x     Document Type: Article

References (45)

1. Ho KLL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88:107-15.
2. Cleland JGF, Tygesen K, Uretsky BF, Armstrong P, Horowitz JD et al. on behalf of the ATLAS Investigators. Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS Study. Eur Heart J 2001;22:1601-12.
3. Bowker TJ, Wood DA, Davies MJ. Sudden unexpected cardiac death: methods and results of a national pilot survey. Int J Cardiol 1995;52:241-50.
4. Farb A, Tang AL, Burke AP, Sessums L, Liang Y, Virmani R. Sudden coronary death: Frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. Circulation 1995;92:1701-9.
5. Davies MJ. Anatomic features in victims of sudden coronary death. Circulation 1992;85(Suppl. I):I-19-I-24.
6. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
7. Gibbs CR, Blann AD, Watson RD, Lip GYH. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm. Circulation 2001;103:1746-51.
8. Lip GYH, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol 1999;33:1424-6.
9. Kerr R, Stirling D, Ludlam CA. Interleukin-6 and haemostasis. Br J Haematol 2001;155:3-12.
10. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060-7.
11. McVey JH. Tissue factor pathway. Baillieres Best Pract Res Clin Haematol 1999;12:361-72.
12. Ng TMH, Cheang KI, Munger MA, Callahan KS. Neurohormonal activation does not explain elevated tissue factor expression in heart failure. Thromb Haemost 2002;87:176-7.
13. Chin SP, Chung NAY, Gibbs CR, Blann AD, Lip GYH. Vascular endothelial growth factor and soluble P-selectin in acute and chronic heart failure. Am J Cardiol 2002;90:1258-60.
14. Kuenen BC, Levi M, Meijers JC, Kakkar AK, van Hinsbergh VW, Kostense PJ, et al. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/receptor pathway in cancer patients. Arterioscl Thromb Vasc Biol 2002;22:1500-5.
15. Shoji M, Hancock WW, Abe K, Micko C, Casper KA, Baine RM et al. Activation of coagulation and angiogenesis in cancer. Am J Pathol 1998;152:399-411.
16. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996;2:209-15.
17. Rickles FR, Shoji M, Abe K. The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin depostition and angiogenesis in cancer. Int J Haematol 2001;73:145-50.
18. Chung NAY, Belgore F, Li Saw He FL, Conway DSG, Blann AD, Lip GYH. Is the hypercogulable state in atrial fibrillation mediated by vascular endothelial growth factor? Stroke 2002;33:2187-91.
19. Blann AD, Belgore FM, McCollum CN, Silverman S, Lip PL, Lip GYH. Vascular endothelial growth factor and its receptor Flt-1 in the plasma of patients with coronary and peripheral atherosclerosis and type II diabetes. Clin Sci 2002;102:187-94.
20. Altman DG. Practical Statistics for Medical Research. London: Chapman & Hall, 1991.
21. Raymond RJ, Dehmer GJ, Theoharides TC, Deliargyris EN. Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction. Am Heart J 2001;141:435-8.
22. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the vesnarinone trial (VEST). Circulation 2001;103:2055-9.
23. Aukrust P, Ueland T, Lien E, Bendtzen K, Muller F, Andreassen AK et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999;83:376-82.
24. Lommi J, Pulkki K, Koskinen P, Naveri H, Leinonen H, Harkonen M et al. Haemodynamic, neuroendocrine and metabolic correlates of circulating cytokine concentrations in congestive heart failure. Eur Heart J 1997;18:1620-5.
25. Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, Tsutsui T et al. High levels of brain natriuretic peptide and interleukin-6 after optimised treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1587-93.
26. Orus J, Roig E, Perez-Villa F, Pare C, Azqueta M, Filella X et al. Prognostic value of serum cytokines in patients with congestive heart failure. J Heart Lung Transplant 2000;19:419-25.
27. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998;31:391-8.
28. Bevilacqua MP, Pober JS, Majeau GR, Catran RS, Gimbrone MA. Interluekin-1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984;160:618-23.
29. Osterud B. Tissue factor expression by monocytes: regulation and pathophysiological roles. Blood Coagul Fibrinolysis 1998;9 (Suppl. 1):S9-S14.
30. de Boer RA, Siebelink NMJ, Tio RA, Boomsma F, van Veldhuisen DJ. Carvedilol increases plasma VEGF in patients with chronic heart failure. Eur J Heart Fail 2001;3:331-3.
31. Abraham D, Hofbauer R, Schafer R, Blumer R, Paulus P, Miksovsky A et al. Selective downregulation of VEGF-A (165), VEGF-R (1), and decreased capillary density in patients with dilative but not ischemic cardiomyopathy. Circ Res 2000;87:644-7.
32. Gustafsson T, Bodin K, Sylven C, Gordon A et al. Increased expression of VEGF following exercise training in patients with heart failure. Eur J Clin Invest 2001;31:362-6.
33. Banai Shweiki D, Pinson A, Chandra M, Lazarovici G, Keshet E. Up-regulation of vascular endothelial growth factor expression induced by myocardial ischemia: implications for coronary angiogenesis. Cardiovasc Res 1994;28:1176-9.
34. Marti HJ, Bernaudin M, Bellail A, Schoch H, Ealer M, Petit E, Risan W. Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. Am J Pathol 2000;156:965-76.
35. Slevin M, Krupinski J, Slowik A, Kumar P, Szczudlika A, Gaffrey J. Serial measurement of vascular endothelial growth factor and transforming growth factor-beta1 in serum of patients with acute ischemic stroke. Stroke 2000;8:1863-70.
36. Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor (VEGF) in C6 glioma cells. J Biol Chem 1995;270:19761-6.
37. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-39.
38. Camera M, Giesen PL, Fallon J, Aufiero BM, Taubman M, Tremoli E et al. Cooperation between VEGF and TNF-alpha is necessary for exposure of active tissue factor on the surface of human endothelial cells. Arterioscler Thromb Vasc Biol 1999;19:531-7.
39. Matsunanaga T, Warltier DC, Weihrauch DW, Moniz M, Tessmer J, Chilian WM. Ischemia-induced coronary collateral growth is dependent on vascular endothelial growth factor and nitric oxide. Circulation 2000;102:3098-103.
40. Varin R, Mulder P, Tamion F, Richard V, Henry JP, Lallemand F et al. Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure: Role of nitric oxide, prostanoids, oxidant stress and bradykinin. Circulation 2000;102:351-6.
41. Lip GYH. Fibrinogen and cardiovascular disorders. Q J Med 1995;88:155-65.
42. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. Meta-analysis of prospective studies. JAMA 1998;279:1477-82.
43. Smith FB, Lee AJ, Hau CM, Rumley A, Lowe GDO, Fowkes FGR. Plasma fibrinogen, haemostatic factor and prediction of peripheral arterial disease in the Edinburgh Artery Study. Blood Coag Fibrinolysis 2000;11:43-50.
44. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. For the ECAT Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-41.
45. Seljeflot M, Hurlen M, Arnesen H. Levels of soluble tissue factor are related to future clinical events in patients with previous myocardial infarction. J Thromb Haemostas 2003;1 (Suppl.):PO495.